Core Viewpoint - *ST Tianmao's stock will be delisted from the Shenzhen Stock Exchange, with the decision effective immediately, and the stock will be removed within five trading days [1][2]. Group 1: Delisting Announcement - On September 25, *ST Tianmao received a notice from the Shenzhen Stock Exchange regarding the termination of its stock listing [1]. - The stock will not enter a delisting transition period and will be delisted within five trading days from the announcement [2]. Group 2: Shareholder Meeting and Cash Option - On August 25, *ST Tianmao held an extraordinary general meeting where shareholders approved the decision to voluntarily terminate the stock listing [5]. - The company initiated a cash option mechanism to protect investors, allowing eligible A-share shareholders to exercise cash options at a price of 1.60 yuan per share, with a total of 1,442,279,537 cash options effectively declared during the application period [5]. - The total funding required for the cash options is approximately 2.3 billion yuan [5]. Group 3: Post-Delisting Arrangements - After delisting, *ST Tianmao's shares will be transferred to the National Equities Exchange and Quotations system for trading [6]. - The company has appointed Changcheng Guorui as the agency to manage the share transfer services [6].

Group 1: Strategic Restructuring - Pingmei Shenma and Shenneng Group announced plans for strategic restructuring by the controlling shareholders, which will not significantly impact their operations [1][1] - The restructuring will not change the controlling shareholders or the actual controllers of either company [1][1] Group 2: Capital Increase - Ganfeng Lithium plans to introduce investors for a capital increase of up to 2.5 billion yuan for its subsidiary, Ganfeng Lithium Technology [2] - The capital increase will be priced at 3 yuan per 1 yuan of registered capital, and the company will waive its preferential subscription rights [2] Group 3: Stock Trading Suspension - Upwei New Materials' stock has been suspended for verification due to multiple instances of abnormal trading fluctuations [3] - The company will conduct an investigation into the trading volatility and will resume trading after the verification process [3] Group 4: Earnings Forecast - Jihong Co. expects a net profit of 209 million to 222 million yuan for the first three quarters of 2025, representing a growth of 55% to 65% year-on-year [4] - The growth is attributed to significant increases in revenue and profit from cross-border social e-commerce and improved operational efficiency in the packaging business [4] Group 5: Fundraising and Projects - Hanyu Pharmaceutical plans to raise up to 968 million yuan through a private placement for various projects including peptide drug production and R&D upgrades [5] - Water Development Gas received acceptance for its securities issuance application from the Shanghai Stock Exchange [6] Group 6: Important Transactions - Tianqi Model's controlling shareholders signed a share transfer agreement to transfer 162 million shares, which will change the controlling shareholder to Jianfa Wanyu [7] - The transaction is expected to lead to a change in the actual controller to the Urumqi Economic and Technological Development Zone State-owned Assets Supervision and Administration Commission [7] Group 7: Investment Projects - Dongfang Yuhong signed an investment agreement to invest 600 million yuan in a new materials industry chain project in Nanning, Guangxi [9] - The project includes mining, processing, and product development [9] - Changqing Group plans to invest 571 million yuan in the second phase of its cogeneration project in Maoming [9]

Core Viewpoint - Han Yu Pharmaceutical plans to raise up to 968 million yuan through a private placement of A-shares, primarily to fund the expansion of its peptide drug production line, the development of Semaglutide, and to supplement working capital [1][2] Group 1: Fund Allocation - The company intends to allocate 495 million yuan for the expansion of the peptide drug production line and green intelligent projects [1] - 98 million yuan is earmarked for the Semaglutide development project, with 25 million yuan for the domestic injectable form and 73 million yuan for the oral form in the U.S. [1] - 280 million yuan will be used to supplement working capital [1] Group 2: Market Opportunity - The global GLP-1 drug market is expected to exceed 33.6 billion dollars in sales by mid-2025, with annual sales projected to surpass 60 billion dollars [1] - Semaglutide and other GLP-1 products are experiencing rapid growth and expanding indications, which will further increase market potential [1][2] Group 3: Business Strategy - The expansion project aims to enhance the company's large-scale production capacity for peptide raw materials, ensuring a continuous supply of raw materials to meet growing market demand [2] - The company aims to accelerate the research and registration process for Semaglutide formulations, enhancing its product diversity and competitiveness in the GLP-1 drug sector [2] Group 4: Financial Performance - In the first half of the year, Han Yu Pharmaceutical achieved a revenue of 549 million yuan, a significant increase of 114.86% year-on-year, and a net profit of 145 million yuan, marking a turnaround from losses [3] - The revenue growth is attributed to the expansion of the company's international formulation business and the approval of Liraglutide injection by the U.S. FDA, which is expected to boost sales [3]

Group 1: Investment and Fundraising - Hanyu Pharmaceutical plans to raise no more than 968 million yuan for the development of semaglutide and other projects [1] - Ganfeng Lithium intends to introduce investors for a capital increase of up to 2.5 billion yuan [9] Group 2: Strategic Restructuring - Pingmei Shenma Holdings is undergoing a strategic restructuring as directed by the Henan provincial government, which will not affect the company's operations significantly [2][8] - Shennong Holdings is also involved in a strategic restructuring with no change in control or significant impact on operations [7][8] Group 3: Clinical Trials and Approvals - XinNuoWei's subsidiary received approval for clinical trials of a drug for treating mild Alzheimer's disease, marking a significant milestone in the development of biosimilar drugs [3] - Tainkang's subsidiary has received approval for clinical trials of CKBA cream for rosacea, a first-class innovative drug in China [4] - Baili Tianheng's drug, iza-bren, has been included in the list of breakthrough therapies, indicating its potential in treating advanced urinary tract cancer [5] Group 4: Contracts and Projects - Zhongyou Engineering signed an EPC contract worth 2.524 billion USD for a seawater pipeline project in Iraq, expected to positively impact future revenues [6]

Group 1 - The company, Hanyu Pharmaceutical, announced that it will hold a board and supervisory board meeting on September 25, 2025, to review the proposal for a specific issuance of A-shares [1] - The relevant proposal and announcement have been disclosed on the Giant Tide Information Network [1] - The issuance of shares is subject to approval by the Shenzhen Stock Exchange and registration consent from the China Securities Regulatory Commission [1]

Core Viewpoint - Hanyu Pharmaceutical (300199.SZ) plans to issue A-shares to specific investors, aiming to raise up to 968 million yuan for various projects and working capital [1] Group 1: Share Issuance Details - The company intends to issue shares to no more than 35 specific investors, with the issuance price set at no less than 80% of the average trading price over the 20 trading days prior to the pricing benchmark [1] - The total number of shares issued will be determined by dividing the total amount raised by the issuance price, not exceeding 30% of the total share capital before the issuance [1] Group 2: Use of Proceeds - The raised funds will be allocated entirely to the expansion of peptide drug production lines and green intelligent upgrades, expansion of peptide fragment production, upgrading of research laboratories, development of Semaglutide, and to supplement working capital [1]

Core Viewpoint - Hanyu Pharmaceutical plans to raise a total of up to RMB 968 million through a private placement, with the net proceeds allocated to various projects including peptide drug production and R&D upgrades [1] Fundraising Purpose - The funds will be used for the expansion of peptide drug production lines and green intelligent upgrades [1] - Additional allocations include the construction of peptide fragment production projects and the upgrade of R&D laboratories [1] - Specific projects also include the development of Semaglutide and its domestic injectable and oral formulations for diabetes treatment [1] - A portion of the funds will be used to supplement working capital [1]

Core Viewpoint - Han Yu Pharmaceutical plans to raise no more than 968 million yuan through a private placement of A-shares, aimed at addressing project investment and R&D funding needs, thereby alleviating financial pressure and enhancing risk resilience [1] Fundraising Details - The company intends to use the net proceeds from the fundraising for multiple projects, including the expansion of peptide drug production lines, green intelligent upgrades, peptide fragment production expansion, laboratory upgrades, and the development of Semaglutide [1] Financial Implications - The fundraising is expected to help the company manage its operational and R&D activities more effectively, ensuring a reasonable arrangement of resources and improving its ability to withstand financial risks [1]

每经头条（nbdtoutiao）——"9·24"一周年，A股总市值破116万亿元！四大变革重塑中国资本市场新生 态 （记者 张喜威） 每经AI快讯，翰宇药业9月25日晚间发布公告称，公司第六届第七次董事会会议于2025年9月25日在公 司龙华总部2006董事会会议室以现场结合通讯方式召开。会议审议了《关于公司2025年度向特定对象发 行股票方案的议案》等文件。 ...

Core Viewpoint - Han Yu Pharmaceutical announced the approval of a private placement of A-shares, aiming to raise up to RMB 968 million for various projects, while cautioning investors about potential uncertainties in the process [1] Summary by Categories Fundraising Details - The private placement will involve no more than 35 specific investors [1] - The issuance price will be no less than 80% of the average trading price of the company's stock over the 20 trading days prior to the pricing date [1] - The total amount to be raised is up to RMB 968 million [1] Allocation of Funds - The funds will be allocated to several projects: - Peptide drug production line and green intelligent expansion project: Total investment of approximately RMB 549 million, with RMB 495 million from the raised funds [1] - Peptide fragment expansion construction project: Total investment of RMB 45.8 million, with RMB 40 million from the raised funds [1] - R&D laboratory upgrade project: Total investment of RMB 57.75 million, with RMB 55 million from the raised funds [1] - Semaglutide R&D project: Total investment of approximately RMB 133 million, with RMB 98 million from the raised funds [1] - Semaglutide domestic injection (for diabetes indication) project: Total investment of RMB 57 million, with RMB 25 million from the raised funds [1] - Semaglutide oral tablet (for diabetes indication) project for the U.S. market: Total investment of RMB 75.8 million, with RMB 73 million from the raised funds [1]